Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...
Zacks.com on MSN10d
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...
Los Angeles Times18d
FDA approval of Kisunla brings change to Alzheimer’s
The U.S. Food and Drug Administration (FDA) has taken a move in the management of Alzheimer’s disease by approving a drug known as Kisunla (donanemab-azbt). Kisunla focuses on patients diagnosed with ...
Morningstar12d
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli ...
Stockhouse12d
Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly ...
Medindia12d
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
Kisunla was first approved in the United States in July 2024 Japan is the second major market in which Kisunla has been approved for use. In Japan, by 2030, the number of patients with dementia is ...